SCHEMBL4236569

SCHEMBL4236569

CCCCN1CCC(CNc2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(CC)CC)cc4OC)cc3)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 7/20 0.46
HTR4 Q13639 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
PKM P14618 1/20 0.41
MCHR2 Q969V1 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
ADRA2C P18825 1/20 0.40
CHRM3 P20309 1/20 0.40
HTR1D P28221 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240511 0.93 SSTR5 (0.42) MCHR1HTR4SMN1; SMN2NPSR1MEN1
SCHEMBL4233894 0.90 MCHR1 (0.47) MCHR1HTR4SMN1; SMN2NPSR1MEN1
SCHEMBL4236062 0.90 MCHR1 (0.47) MCHR1HTR4SMN1; SMN2NPSR1MEN1
SCHEMBL4232415 0.89 HTR4 (0.43) MCHR1HTR4SMN1; SMN2NPSR1MAPT
SCHEMBL4236698 0.87 SMN1; SMN2 (0.46) MCHR1HTR4SMN1; SMN2NPSR1MEN1
SCHEMBL4236573 0.87 MCHR1 (0.45) MCHR1HTR4SMN1; SMN2NPSR1MEN1
SCHEMBL4234367 0.86 SSTR5 (0.42) MCHR1MEN1GAAMAPTKMT2A
SCHEMBL13699148 0.85 SMN1; SMN2 (0.44) MCHR1HTR4SMN1; SMN2NPSR1MEN1
SCHEMBL4233219 0.85 SMN1; SMN2 (0.44) MCHR1HTR4SMN1; SMN2NPSR1MEN1
SCHEMBL4683904 0.85 MCHR1 (0.36) MCHR1HTR4SMN1; SMN2NPSR1MCHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MCHR1 47/4885HTR4 102/4885SMN1; SMN2 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.